Efficacy of hIFN-β expression against primary AML cells in vivo. (A) Plasma hIFN-β levels in β2m^null NOD/SCID mice following AAV2/8-mediated transduction at different vector doses. Measurements were made in duplicates on 2 separate occasions. (B) Effects of plasma hIFN-β levels on primary AML proliferation in vivo; quantitative results from FACS analysis of bone marrow.